HOT NEWS

Industry News

News image

Bayer HealthCare joins forces with Stroke Alliance for Europe

Ahead of the "Move for Health Day" (10 May) and the "European Stroke Day" (14 May), the Stroke Alliance for Eu...

News image

Sanofi strengthens its French-German partnership

Sanofi (EURONEXT: SAN and NYSE: SNY) announced its involvement in two major Franco-German projects in the fiel...

News image

Merck Serono to finance the launch of the EspeRare Foundation

Merck Serono, a division of Merck, Darmstadt, Germany, today announced the launch of the EspeRare Foundation, ...

News image

Bayer HealthCare to broaden strategic alliance with German Cancer Research Center

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic r...

More in: Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Novo Nordisk, Novartis, Roche, Sanofi, Boehringer Ingelheim, Merck KGaA, Abbott, Nycomed, Schering-Plough, Merck, Genzyme, Lilly, Bristol-Myers Squibb, Shire, Amgen, UCB, Lundbeck

Tuesday, 14 May 2013   
EUROPAIN addresses challenges in the treatment of chronic pain
Chronic pain is invisible, but for the people suffering from this hard-to-treat problem, it can be overwhelming. In the IMI project EUROPAIN, scientists from research institutions, universities and pharmaceutical companies have come together to learn more about the basic biology behind chronic pain. This will create a solid knowledge base to speed the development of drugs, known as analgesics, to treat pain. Around one in five adults in Europe have chronic (long-term) pain, i.e. lasting for more than six months, and on average for about seven years. A fifth of sufferers have had pain for more than 20 years, and many end up having to give up work. There are many treatments available for pain, both on prescription and over the counter, but few are effective against chronic pain, and many come with unpleasant or even dangerous side effects.
 
Monday, 13 May 2013   
European Medicines Agency simplifies processing of fee reductions for orphan medicines
European Medicines Agency (EMA)The European Medicines Agency has cancelled the procedure by which sponsors of medicines with an orphan designation need to inform the Agency of their intention to submit an application in order to be eligible for a fee reduction. This forms part of the Agency's effort to reduce administrative burden for applicants and streamline the procedures for fee reductions. Medicines that have been granted orphan designation by the European Commission on the recommendation of the Agency's Committee for Orphan Medicinal Products (COMP) are eligible for fee reductions for a range of regulatory activities.
 
Friday, 10 May 2013   
Meet the Speakers, Read the Program: Doctors 2.0 & You
6 - 7 June 2013, Paris, France.
The activities at Doctors 2.0 & You will include +70 Speakers, presenting real-life examples of the use of healthcare social media and applications. Additional animations will include 13 start-ups, 15 poster presenters, and the exhibitors. Speakers come from 20 countries across Europe, the Middle East, North America, Asia, and Australia. They include 19 practicing healthcare professionals and 15 ePatients. Over 30 of the +70 speakers have created their own employment in digital health, from individual experts on to heads of companies and not for profits. 25 of the +70 are women, which is an exceptional percentage in digital health, especially in a conference occurring outside the US.
 

Research & Development

EUROPAIN addresses challenges in the treatment of chronic pain

Chronic pain is invisible, but for the people suffering from this hard-to-treat problem, it can be overwhelming. In the IMI...

TB, HIV and malaria vaccine research gets major boost

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing...

EU-AIMS - paving the way for new diagnostics and treatments in autism

IMI's EU-AIMS (European Autism Interventions - A Multicentre Study for Developing New Medications) project is making breakthroughs in research into...

Study opens new prospects for developing new targeted therapies for breast cancer

A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important...

More in: Research & Development

Conferences & Events

Meet the Speakers, Read the Program: Doctors 2.0 & You

6 - 7 June 2013, Paris, France. The activities at Doctors 2.0 & You will include +70 Speakers, presenting real-life examples of the use of healthcare social media and applications....

The world's leading heart failure congress

25 - 28 May 2013, Lisbon, Portugal. The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. More than 1,500 scientific...

8th EU Pharma Regulatory Law conference

18 - 19 September 2013, London, United Kingdom. 2013 has presented a unique set of challenges to the pharmaceutical industry. Transparency is becoming ever more prevalent in all aspects of...

Region Southern Denmark launches an international congress on future innovation in healthcare

30 September - 1 October 2013, Odense, Denmark. Denmark will over the next ten years, spend € 5.5 billion on the construction of eight new super hospitals, including the new...

eHealth Week 2013: New Technologies, New Ideas, New Opportunities

13 - 15 May 2013, Dublin, Ireland.Taking place at The Convention Centre Dublin, the event will showcase the world's most cutting edge Health IT technology. eHealth Week is a dedicated...

More in: Conferences & Events

EC Pharmaceuticals

New symbol to identify medicines undergoing additional monitoring

News image

An inverted triangle will shortly appear on the inside leaflet of certain medicinal products on the EU market, following a legal act adopted by the European Commission today. The symbol...

Launch of EU Rapid Alert platform for human Tissues and Cells

News image

A secure alert platform launched by the European Commission will improve the safety of patients undergoing transplantation and medical procedures involving human tissues and cells, e.g. bone marrow, cornea, skin,...

Commission proposes faster access to medicines for patients

News image

Medicines should enter the market faster. With this intention the European Commission has proposed today to streamline and reduce the duration of national decisions on pricing and reimbursement of medicines....

Pricing and reimbursement of medicines: Commission consults on EU transparency rules

News image

The European Commission has launched a public consultation in view of modernising rules on the transparency of Member States’ decisions regarding the pricing and reimbursement of medicines. The consultation invites...

Call for proposals under the Innovative Medicines Initiative Joint Undertaking Third Call

News image

The Innovative Medicines Initiative (IMI) is a public-private partnership aiming to improve the drug development process. The European Commission's Seventh Framework Programme contributes EUR 1 billion to the IMI research...

More in: European Commission

EMA News

European Medicines Agency simplifies processing of fee reductions for orphan medicines

News image

The European Medicines Agency has cancelled the procedure by which sponsors of medicines with an orphan designation need to inform the Agency of their intention to submit an application in...

Recommendation to suspend tetrazepam-containing medicines endorsed by CMDh

News image

Following the recent recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC), the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) has endorsed by majority the PRAC recommendation...

Stem cell therapy treatments

News image

Concerns have been raised in the media about certain stem cell therapy treatments. These sorts of new techniques potentially offer exciting possibilities to patients for the treatment of a range...

European Medicines Agency publishes report on patient recruitment and geographical location of clinical trials

News image

Almost 62% of the patients in pivotal trials submitted in marketing-authorisation applications (MAAs) to the European Medicines Agency between January 2005 and December 2011 were recruited outside of the European...

More in: EMA